15 Biggest Mid-Day Gainers For Tuesday - Affimed (NASDAQ:AFMD), Amarin Corp (NASDAQ:AMRN)

Avenue Therapeutics Inc ATXI shares gained 32 percent to $7.92. Avenue Therapeutics priced its 5.5 million share IPO at $6.00 per share.
Chicago Bridge & Iron Company N.V. CBI shares surged 19.2 percent to $17.16. Delaware Supreme Court ruled in favor of Chicago Bridge & Iron in dispute with Westinghouse Electric, Reuters reported.
Strongbridge Biopharma plc SBBP shares climbed 12.6 percent to $6.70 as the company disclosed that it has completed its enrollment target of 90 patients in the Phase 3 SONICS study evaluating RECORLEV™ for the treatment of endogenous Cushing’s syndrome.
Zion Oil & Gas, Inc. ZN shares rose 12.6 percent to $3.12.
Handy & Harman Ltd HNH shares jumped 11.8 percent to $31.85 after Steel Partners Holdings LP SPLP agreed to acquire the remaining outstanding shares of Handy & Harman.
Cobalt International Energy, Inc. CIE shares rose 10.7 percent to $2.68.
SurModics, Inc. SRDX climbed 10.2 percent to $27.83. Aegis Capital initiated coverage on SurModics with a Buy rating.
CARBO Ceramics Inc. CRR shares surged 7.7 percent to $6.86.
Amarin Corporation plc (ADR) AMRN shares gained 6.2 percent to $3.66. Cantor Fitzgerald assumed coverage on Amarin with an Overweight rating and a price target of $10.00.
Sprint Corp S shares rose 5.6 percent to $8.46 after Wall Street Journal reported a possible wireless partnership with Charter and Comcast.
NxStage Medical, Inc. NXTM shares gained 5 percent to $24.58. Craig-Hallum initiated coverage on NxStage Medical with a Buy rating.
Affimed NV AFMD shares climbed 4.7 percent to $2.25. Affimed presented preclinical data for AFM24 and AFM26 programs at the EACR-AACR-SIC 2017.
J C Penney Company Inc JCP rose 4.7 percent to $4.89. Gordon Haskett upgraded J C Penney from Reduce to Hold.
Darden Restaurants, Inc. DRI gained 4.6 percent to $94.21 after the company reported stronger-than-expected results for its fourth quarter.
Arena Pharmaceuticals, Inc. ARNA rose 4.4 percent to $15.75. Citigroup initiated coverage on Arena Pharmaceuticals with a Buy rating.

Market News and Data brought to you by Benzinga APIs